EGFR BATs is under clinical development by Transtarget and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I drugs for Gliosarcoma does not have sufficient historical data to ...

EGFR BATs is under clinical development by Transtarget and currently in Phase I for Glioblastoma Multiforme (GBM).

Patients with advanced lung tumors harboring EGFR exon 19 deletions or exon 21 L858R mutations are eligible for the combo treatment.

A panelist discusses how infusion-related reactions to monoclonal antibodies in EGFR-mutated NSCLC can be effectively managed through preventive measures demonstrated in the phase 2 SKIPPirr trial.

MabGenesis, a biotechnology company specializing in antibody drug development, announced on the 24th that it has raised 470 million yen (approximately $3.2 million) in its latest funding round.

Diamond Strike 100,000 Janssen releases Phase 1 results of EGFR-MET bispecific antibody effective in refractory lung cancer A hundred-regiment wa ...

INR:6695. rummy 9999 Johnson & Johnson's EGFR-MET dual antibody registration starts first-line non-small cell lung cancer Phase III clinical trial Medical equipment co ...